Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MAPK8
REST API REST API
Homo sapiens
MAPK8 is differentially expressed in 296 experiments: 132 organism parts: bone marrow, cerebellum, ... (130 more);, 199 disease states: normal, breast carcinoma, ... (197 more);, 98 cell types 422 cell lines 37 compound treatments and 76 other conditions.
Synonyms JNK, SAPK1, PRKM8, JNK1
Orthologs HOG1 (Saccharomyces cerevisiae)   Q4H3A2_CIOIN (Ciona intestinalis)   Mapk8 (Mus musculus)   MAPK8 (Bos taurus)   MAPK8 (Gallus gallus)   MK08_RAT (Rattus norvegicus)   mapk8 (Xenopus laevis)   MAPK8 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term response to UV, Toll signaling pathway, cytosol, JUN kinase activity, protein binding, apoptosis, phosphotransferase activity, alcohol group as acceptor, JUN phosphorylation, cytoplasm, peptidyl-serine phosphorylation, innate immune response, membrane, negative regulation of apoptosis, response to stress, protein tyrosine kinase activity, stress-activated MAPK cascade, regulation of protein localization, MAP kinase activity, histone deacetylase binding, response to cadmium ion, ATP binding, transferase activity, transferring phosphorus-containing groups, nucleus, nucleotide binding, kinase activity, protein serine/threonine kinase activity, JNK cascade, nucleoplasm, catalytic activity, peptidyl-threonine phosphorylation, lipopolysaccharide biosynthetic process, protein kinase activity, mitochondrion, toll-like receptor 4 signaling pathway, activation of pro-apoptotic gene products, negative regulation of protein binding, toll-like receptor signaling pathway, cellular response to mechanical stimulus, induction of apoptosis by intracellular signals, ossification, positive regulation of deacetylase activity, toll-like receptor 3 signaling pathway, induction of apoptosis by extracellular signals, nerve growth factor receptor signaling pathway, toll-like receptor 2 signaling pathway, induction of apoptosis in response to chemical stimulus, MyD88-dependent toll-like receptor signaling pathway, histone deacetylase regulator activity, protein phosphorylation, MyD88-independent toll-like receptor signaling pathway, regulation of sequence-specific DNA binding transcription factor activity, regulation of histone deacetylation, positive regulation of determination of dorsal identity, toll-like receptor 1 signaling pathway
InterPro Term Aminoglycoside_PTrfase, Prot_kinase_cat_dom, RIO-like_kinase, JNK_MAPK, LipoPS_kinase, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession C9J762, A1L4K2, Q308M2, C9JWQ4, A6NF29, P45983
Search EB-eye ENSG00000107643
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-6573, E-MEXP-433, E-GEOD-3526, E-MTAB-62, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (37 experiments)

Factor Value U/D Experiments
BT474
3
E-MEXP-440, E-MTAB-37, E-MTAB-62
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
A549
2
E-GEOD-3202, E-GEOD-6013
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
K562
2
E-MTAB-37, E-GEOD-24147
MOLT4
2
E-MTAB-37, E-MTAB-62
416 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (46 experiments)

Factor Value U/D Experiments
plasma cell
2
E-MEXP-2360, E-GEOD-6691
embryonic stem cell
2
E-MEXP-930, E-GEOD-26672
mononuclear
2
E-GEOD-26672, E-GEOD-13987
monocyte
1
2
E-GEOD-22373, E-GEOD-11755, E-GEOD-5099
leydig cell
1
E-MTAB-25
BDCA4+ dentritic cells
1
1
E-AFMX-5
92 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1615, E-GEOD-15960, E-GEOD-2466, E-TABM-15, ... (63 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-3726
control
1
3
E-GEOD-21912, E-GEOD-8121, E-GEOD-16363, E-GEOD-20602
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
melanoma
2
E-MTAB-37, E-GEOD-7307
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
uterine fibroid
2
E-GEOD-7307, E-MTAB-62
193 more value(s).


Compound treatment

studied in E-GEOD-5258, E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (30 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
none
5
6
E-MEXP-1958, E-GEOD-412, E-TABM-782, E-GEOD-20719, E-MEXP-1230, ... (11 experiments)
control - keratinocyte growth factor
1
E-GEOD-7216
ponasterone A
1
E-GEOD-3113
MIG control
1
E-GEOD-15811
NaOH
1
E-MEXP-2590
31 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-22513, E-GEOD-1563, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, E-GEOD-4667 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-MEXP-2280, E-TABM-147, ... (9 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MEXP-2340, ... (6 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-TABM-321, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-MEXP-2657, E-GEOD-20540, E-MEXP-1446, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-974, E-GEOD-2466, ... (34 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, E-GEOD-980, ... (6 experiments)

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-7819, E-GEOD-19703, E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, ... (7 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7307, E-GEOD-16363

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.396 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM